Citicolina: revisión farmacológica y clínica, actualización 2022

This review is based on the previous one published in 2016 (Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol 2016; 63 (Supl 3): S1-S73), incorporating 176 new references, having all the information available in the same document to facilitate the access to the inf...

Descripción completa

Detalles Bibliográficos
Autores principales: Secades, Julio J., Gareri, Pietro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Viguera Editores (Evidenze Group) 2022
Materias:
Revisión
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548480/
http://dx.doi.org/10.33588/rn.75S05.2022311
_version_ 1785115274942349312
author Secades, Julio J.
Gareri, Pietro
author_facet Secades, Julio J.
Gareri, Pietro
author_sort Secades, Julio J.
collection PubMed
description This review is based on the previous one published in 2016 (Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol 2016; 63 (Supl 3): S1-S73), incorporating 176 new references, having all the information available in the same document to facilitate the access to the information in one document. This review is focused on the main indications of the drug, as acute stroke and its sequelae, including the cognitive impairment, and traumatic brain injury and its sequelae. There are retrieved the most important experimental and clinical data in both indications.
format Online
Article
Text
id pubmed-10548480
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Viguera Editores (Evidenze Group)
record_format MEDLINE/PubMed
spelling pubmed-105484802023-10-05 Citicolina: revisión farmacológica y clínica, actualización 2022 Secades, Julio J. Gareri, Pietro Rev Neurol Revisión This review is based on the previous one published in 2016 (Secades JJ. Citicoline: pharmacological and clinical review, 2016 update. Rev Neurol 2016; 63 (Supl 3): S1-S73), incorporating 176 new references, having all the information available in the same document to facilitate the access to the information in one document. This review is focused on the main indications of the drug, as acute stroke and its sequelae, including the cognitive impairment, and traumatic brain injury and its sequelae. There are retrieved the most important experimental and clinical data in both indications. Viguera Editores (Evidenze Group) 2022-12-31 /pmc/articles/PMC10548480/ http://dx.doi.org/10.33588/rn.75S05.2022311 Text en Copyright: © Revista de Neurología https://creativecommons.org/licenses/by-nc-nd/4.0/Revista de Neurología trabaja bajo una licencia Creative Commons
spellingShingle Revisión
Secades, Julio J.
Gareri, Pietro
Citicolina: revisión farmacológica y clínica, actualización 2022
title Citicolina: revisión farmacológica y clínica, actualización 2022
title_full Citicolina: revisión farmacológica y clínica, actualización 2022
title_fullStr Citicolina: revisión farmacológica y clínica, actualización 2022
title_full_unstemmed Citicolina: revisión farmacológica y clínica, actualización 2022
title_short Citicolina: revisión farmacológica y clínica, actualización 2022
title_sort citicolina: revisión farmacológica y clínica, actualización 2022
topic Revisión
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10548480/
http://dx.doi.org/10.33588/rn.75S05.2022311
work_keys_str_mv AT secadesjulioj citicolinarevisionfarmacologicayclinicaactualizacion2022
AT gareripietro citicolinarevisionfarmacologicayclinicaactualizacion2022

Ejemplares similares